Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Teucrium Corn Fund (CORN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Teucrium Corn FundTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Teucrium Corn Fund vs Regeneron Pharmaceuticals Inc — how do they compare? Teucrium Corn Fund trades at $17.58, while Regeneron Pharmaceuticals Inc trades at $806.87 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Teucrium Corn Fund pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Teucrium Corn Fund nearer its low. Which is the better fit depends on your goals.

CORNREGN
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$19.12$812.27
52-Week Low
$16.46$545.94
Market Cap
$83.19B
Enterprise Value
$77.90B
Dividend Yield
0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Teucrium Corn Fund

CORN trades at $17.64, up 0.17% for the day, with technical indicators showing a bearish bias from moving averages despite a neutral oscillator stance and oversold short-term RSI. Recent news highlights strong performance in agricultural ETFs, with CORN returning 9.7% over the past month, driven by inflation trends and geopolitical tensions affecting commodity markets.

The outlook is mixed; positive momentum from commodity strength offers upside, but bearish technicals and reliance on volatile agricultural markets pose risks. Investors should weigh near-term commodity tailwinds against the absence of fundamental financial data and broader market sentiment shifts.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Teucrium Corn Fund

CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.

Read more on CORN

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN